Open Access

TEAD2 as a novel prognostic factor for hepatocellular carcinoma

  • Authors:
    • Jong Seok Joo
    • Sang Yeon Cho
    • Woo Sun Rou
    • Ju Seok Kim
    • Sun Hyung Kang
    • Eaum Seok Lee
    • Hee Seok Moon
    • Seok Hyun Kim
    • Jae Kyu Sung
    • In Sun Kwon
    • Hyuk Soo Eun
    • Byung Seok Lee
  • View Affiliations

  • Published online on: April 6, 2020     https://doi.org/10.3892/or.2020.7578
  • Pages: 1785-1796
  • Copyright: © Joo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

TEA Domain Transcription Factors (TEADs) are important in development and serve essential roles in tumorigenesis; however, the role of TEAD2 expression in hepatocellular carcinoma (HCC) has not been widely examined. The present study was conducted to investigate the expression status of TEAD2 in HCC and to evaluate whether the expression of TEAD2 is associated with the prognosis of patients with HCC. mRNA expression data was retrieved for Hippo pathway genes of 50 normal control and 377 HCC samples from The Cancer Genome Atlas data portal. Gene set enrichment, GeneNeighbors, ClassNeighbors and survival analyses were then performed based on the gene expression levels. The mRNA expression of TEAD2 and VGLL4 was significantly higher in HCC compared with the normal control samples, and the mRNA expression of TEAD2 was higher in advanced stages than in early stages. Specifically, survival analysis revealed that higher mRNA expression of TEAD2 was significantly associated with a less favorable overall survival rate (P=0.0067) and there was a trend towards significance between higher mRNA expression of VGLL4 and poor overall survival rate (P=0.051). According to the gene set enrichment analysis, patients with higher mRNA expression of TEAD2 and VGLL4 had strongly enhanced epithelial‑mesenchymal transition and angiogenesis, which are associated with tumor progression. In conclusion, increased mRNA expression of TEAD2 is associated with a poor prognosis in patients with HCC. TEAD2 may serve as a prognostic factor for HCC and a novel therapeutic target.
View Figures
View References

Related Articles

Journal Cover

June-2020
Volume 43 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Joo JS, Cho SY, Rou WS, Kim JS, Kang SH, Lee ES, Moon HS, Kim SH, Sung JK, Kwon IS, Kwon IS, et al: TEAD2 as a novel prognostic factor for hepatocellular carcinoma. Oncol Rep 43: 1785-1796, 2020
APA
Joo, J.S., Cho, S.Y., Rou, W.S., Kim, J.S., Kang, S.H., Lee, E.S. ... Lee, B.S. (2020). TEAD2 as a novel prognostic factor for hepatocellular carcinoma. Oncology Reports, 43, 1785-1796. https://doi.org/10.3892/or.2020.7578
MLA
Joo, J. S., Cho, S. Y., Rou, W. S., Kim, J. S., Kang, S. H., Lee, E. S., Moon, H. S., Kim, S. H., Sung, J. K., Kwon, I. S., Eun, H. S., Lee, B. S."TEAD2 as a novel prognostic factor for hepatocellular carcinoma". Oncology Reports 43.6 (2020): 1785-1796.
Chicago
Joo, J. S., Cho, S. Y., Rou, W. S., Kim, J. S., Kang, S. H., Lee, E. S., Moon, H. S., Kim, S. H., Sung, J. K., Kwon, I. S., Eun, H. S., Lee, B. S."TEAD2 as a novel prognostic factor for hepatocellular carcinoma". Oncology Reports 43, no. 6 (2020): 1785-1796. https://doi.org/10.3892/or.2020.7578